Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type
' X, X- z+ T8 K* v2 l9 C, KNOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9
4 f! q1 S1 Z$ R4 W+ Author Affiliations! j" R$ h; ?# u- L
$ I3 g6 Y/ F) y2 _
1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan . d3 }, L9 K/ o# t: d3 k
2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
! F2 J6 v6 ^* X6 w1 n) n3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan * Z5 y5 l h( ^: E- h- F
4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
0 r8 a: \7 C8 ^5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan
6 P$ p; N. F( [7 s* F- L6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
5 b9 y4 k2 i; H. P" y7Kinki University School of Medicine, Osaka 589-8511, Japan
3 {! y) Y+ Y p! G- b1 @. Z7 m4 r8Izumi Municipal Hospital, Osaka 594-0071, Japan
" ]$ j& x: t+ k; _& U9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
* y3 ~ j4 U: k1 b- o" eCorrespondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp & c+ W+ U9 Y& H& r6 [) _
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type.
6 ^- J. K% n U' c7 b; Q# q! ~5 E. }3 z f/ X
|